Collagen chosen to take part in €4m research project

Collagen chosen to take part in €4m research project

Collagen Solutions has been chosen to take part in a €4 million (£2.9m) European research project aimed at developing new treatments for Parkinson’s disease.

The company said it will receive “significant funding” to develop various types of medical-grade collagens for investigation during the project, which is looking to progress treatments that are aimed at slowing the progression of the disease rather than just alleviating the symptoms.

The project is being led by CÚRAM, the Centre for Research in Medical Devices based at National University for Ireland in Galway, and is bringing together world-class researchers and industry partners to develop the first disease-modifying therapy for Parkinson’s, which could slow down its progression.

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.